Skip to main content
    1. Home

    • UCB Medicines: Clinical Studies and Scientific Research Publication

    Publications

    This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

    Select product(s):
    Select topic(s):
    Phase:

    *Includes seizure clusters and acute or prolonged seizures

    164 result(s)

    phase 2

    BRIVIACT® (brivaracetam) CV

    Focal Onset Seizures
    View

    Pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients with epilepsy: an open-label trial 

    Mark Kristof Farkas, Harriet Kang, András Fogarasi et al.  February 23, 2022
    phase 4/RWE

    BIMZELX® (bimekizumab-bkzx)

    Plaque Psoriasis
    View

    A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17

    Armstrong W. April, Blauvelt Andrew, Mrowietz Ulrich et al.  February 15, 2022
    phase 4/RWE

    BIMZELX® (bimekizumab-bkzx)

    Plaque Psoriasis
    View

    Bimekizumab self-injection devices: Two multicenter, randomized, open-label studies on self-administration by patients with psoriasis.

    Bagel Jerry, Machala Magdalena, Hellot Scarlett et al.  January 31, 2022
    phase 2

    BIMZELX® (bimekizumab-bkzx)

    Plaque Psoriasis
    View

    Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.

    Frick Andrew, J.G. Krueger, Glatt Sophie et al.  December 27, 2021
    phase 3

    FINTEPLA® (fenfluramine)

    Dravet Syndrome
    View

    Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome

    J Helen Cross, Bradley S Galer, Antonio Gil-Nagel et al.  November 02, 2021
    phase 3

    FINTEPLA® (fenfluramine)

    Dravet Syndrome
    View

    Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: compassionate use program in Germany

    Adam Strzelczyk, Milka Pringsheim, Thomas Mayer et al.  August 10, 2021
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Plaque Psoriasis
    View

    Bimekizumab versus secukinumab in plaque psoriasis.

    Reich Kristian, Warren B. Richard, Lebwohl Mark et al.  July 08, 2021
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Plaque Psoriasis
    View

    Bimekizumab versus adalimumab in plaque psoriasis.

    Warren B. Richard, Blauvelt Andrew, Bagel Jerry et al.  July 08, 2021
    phase 3

    BRIVIACT® (brivaracetam) CV

    Focal Onset Seizures
    View

    Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: post hoc pooled analysis

    Brian D Moseley, Svetlana Dimova, Sami Elmoufti et al.  June 24, 2021
    phase 4/RWE

    CIMZIA® (certolizumab pegol)

    Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
    View

    Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study. 

    van der Horst-Bruinsma I, van Bentum R, Verbraak F et al.  March 29, 2021